Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Blasts More Than 5 Percent of Bone Marrow Nucleated CellsPersistent DiseaseRefractory Acute Myeloid Leukemia

Interventions

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (2)

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

RECRUITING

UC Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

lead

Ohio State University Comprehensive Cancer Center

OTHER